Small molecules with similar structures exhibit Agonist, neutral Antagonist or inverse Agonist activity toward Angiotensin II type 1 receptor

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Miura, Shin ichiro ^a,b   Kiya, Yoshihiro ^a   Hanzawa, Hiroyuki ^c   Nakao, Naoki ^c   Fujino, Masahiro ^a   Imaizumi, Satoshi ^a   Matsuo, Yoshino ^a   Yanagisawa, Hiroaki ^c   Koike, Hiroyuki ^c   Komuro, Issei ^d   Karnik, Sadashiva S ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DAIICHI SANKYO CO   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; OLMESARTAN; R 239470; R 781253; R 781254; R 791212; R 794847; R 795100; R 801832; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN STABILITY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 84862249834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037974     Document Type: Article

References (30)

1. Schneider EH, Strasser A, Thurmond RL, Seifert R, (2010) Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands. J Pharmacol. Exp. Ther. 334, 513-521.
2. Soudijn W, van Wijngaarden I, Ijzerman AP, (2005) Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med. Res. Rev. 25, 398-426.
3. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-744.
4. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497-502.
5. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP, (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187.
6. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-1265.
7. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318, 1266-1273.
8. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469, 236-240.
9. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469, 175-180.
10. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, (2011) The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor. Nature 469, 241-244.
11. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T, (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472.
12. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, (2008) Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol. Endocrinol. 22, 139-146.
13. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, (2006) Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol. Chem. 281, 19288-19295.
14. Soudijn W, van Wijngaarden I, Ijzerman AP, (2005) Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med. Re. Rev. 25, 398-426.
15. Rossier O, Abuin L, Fanelli F, Leonardi A, Cotecchia S, (1999) Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes. Mol. Pharmacol. 56, 858-866.
16. Wang R, Gao Y, Lai L LigBuilder, (2000) A Multi-Purpose Program for Structure-Based Drug Design. J. Mole. Model. 6, 498-516.
17. Schneider G, Fechner U, (2005) Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4, 649-663.
18. Jorgensen WL, (2004) The many roles of computation in drug discovery. Science 303, 1813-1818.
19. Miura S, Feng YH, Husain A, Karnik SS, (1999) Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J. Biol. Chem. 274, 7103-7110.
20. Martin SS, Boucard AA, Clément M, Escher E, Leduc R, (2004) Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. J. Biol. Chem. 279, 51415-51423.
21. Miura S, Zhang J, Boros J, Karnik SS, (2003) TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J. Biol. Chem. 278, 3720-3725.
22. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, (2008) Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep.9, 179-186.
23. Feng YH, Miura S, Husain A, Karnik SS, (1998) Mechanism of activation of AT1 receptor: Role of Asn111 side chain in controlling basal inactivity state. Biochemistry 37, 15791-15798.
24. Noda K, Feng YH, Liu XP, Saad Y, Husain A, (1996) The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35, 16435-16342.
25. Perez DM, Karnik SS, (2005) Multiple signaling states of G-protein coupled receptors. Pharmacol. Rev. 57, 147-161.
26. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E, (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol. Metab. 13, 336-343.
27. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, (2001) Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol. Chem. 276, 29171-29177.
28. Moukhametzianov R, Warne T, Edwards PC, Serrano-Vega MJ, Leslie AG, (2011) Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor. Proc. Natl. Acad. Sci. U S A. 108, 8228-8232.
29. Chen S, Lin F, Xu M, Graham RM, (2002) Phe(303) in TMVI of the alpha(1B)-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. Biochemistry 41, 588-596.
30. Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, (2005) Linking agonist binding to histamine H1 receptor activation. Nat. Chem. Biol. 1, 98-103.